- Home
- OPK
OPK
OPKO Health Inc.
as 03-28-2025 4:00pm EST
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a world supply-chain operation and holding company in Ireland. It also owns a specialty active pharmaceutical ingredients manufacturer in Israel. It operates in two segments Diagnostics and Pharmaceuticals.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | MIAMI |
| Market Cap: | 1.3B | IPO Year: | 1995 |
| Target Price: | $2.75 | AVG Volume (30 days): | 7.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.15 - $2.04 | Next Earning Date: | 05-06-2025 |
| Revenue: | $713,142,000 | Revenue Growth: | -17.41% |
| Revenue Growth (this year): | -2.55% | Revenue Growth (next year): | 6.25% |
Stock Insider Trading Activity of OPKO Health Inc. (OPK)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| FROST PHILLIP MD ET AL | OPK | CEO & Chairman | Mar 17 '25 | Buy | $1.74 | 200,000 | $347,820.00 | 213,501,448 | |
| FROST PHILLIP MD ET AL | OPK | CEO & Chairman | Feb 28 '25 | Buy | $1.71 | 67,434 | $115,312.14 | 213,501,448 | |
| FROST PHILLIP MD ET AL | OPK | CEO & Chairman | Jan 28 '25 | Buy | $1.47 | 47,537 | $70,060.03 | 213,501,448 | |
| FROST PHILLIP MD ET AL | OPK | CEO & Chairman | Jan 17 '25 | Buy | $1.47 | 150,000 | $220,425.00 | 213,501,448 | |
| FROST PHILLIP MD ET AL | OPK | CEO & Chairman | Jan 15 '25 | Buy | $1.48 | 500,000 | $740,850.00 | 213,501,448 |
Latest OPKO Health Inc. News
OPK Breaking Stock News: Dive into OPK Ticker-Specific Updates for Smart Investing
Simply Wall St.
9 days ago
Chairman & CEO of OPKO Health Phillip Frost Buys More Stock
Pharmaceutical Technology
11 days ago
Opko and Entera focus on oral care for obesity and metabolic disorders
MT Newswires
12 days ago
Opko Health Insider Bought Shares Worth $347,820, According to a Recent SEC Filing
MT Newswires
12 days ago
OPKO, Entera to Co-Develop Oral GLP-1/Glucagon Therapy for Obesity
GlobeNewswire
12 days ago
OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders
Barrons.com
15 days ago
Tesla Stock Is Reaching a Breaking Point, Analyst Says. Plus, Vertical Aerospace, OPKO Health, and More.
Insider Monkey
15 days ago
Is OPKO Health, Inc. (OPK) The Best Stock Under $3 to Buy Now?
Zacks
15 days ago
Labcorp is Set to Acquire Select Assets of BioReference Health of OPK
Compare OPK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OPK OPKO Health Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.